Citing the merger documents and his own diligence, Cantor Fitzgerald analyst Louise Chen finds it unlikely that another company would step in for Sucampo Pharmaceuticals (SCMP) as a counter to Mallinckrodt's (BID). Further, Mallinckrodt discounted the value ascribed to Sucampo's pipeline assets, but having a product like Amitiza allows it to limit the purchase price risk, Chen told investors yesterday in a research note. She does not think the January 28 FDA action date for Sucampo's Amitiza pediatric supplemental drug application should be a meaningful stock catalyst. The analyst keeps an Overweight rating on Mallinckrodt with a $42 price target.